April 24, 2013
Synolyne will focus on the research, development and marketing of a patented medical device designed to treat arthrosis by promoting cartilage repair. Synolyne will also use an arthrotic joint supplementation that contains micropearls of KiOmedine-CsU ®, KitoZyme's pure chitosan of non-animal origin .
In January, KitoZyme announced François Blondel as its new CEO. Blondel, 49, was appointed to the company's board of directors on Nov. 30, 2012.
You May Also Like